MedTrace Logo

Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome

NCT00005788 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2012-06-06

No results posted yet for this study

Summary

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill lymphoma cells.

PURPOSE: Phase II trial to study the effectiveness of interleukin-2 in treating patients who have mycosis fungoides or Sezary syndrome.

Conditions

Interventions

BIOLOGICAL

aldesleukin

Sponsors & Collaborators

Principal Investigators

  • Timothy M. Kuzel, MD · Robert H. Lurie Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-04-30
Primary Completion
2002-01-31
Completion
2002-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00005788 on ClinicalTrials.gov